Robert Vries, Ph.D

Chief Executive Officer

Robert received his PhD in Biochemistry from the Leiden University Medical Center on the study of Oncogenic cell transformation. He subsequently moved to Stanford University (USA) to do his Post Doc studying neural stem cells. Upon his return to the Netherlands he continued the study of stem cells in the group of Prof. Hans Clevers at the Hubrecht Institute in The Netherlands.

 

In the group of Hans Clevers he was part of the team that developed the breakthrough technology that allowed the expansion of adult stem cells. The so called Organoid Technology became the basis of the non-profit company ‘Hubrecht Organoid Technology'(HUB) of which he is currently the CEO.

October 18, 2019 CrownBio launched patient-derived tumor organ... San Diego, October 17, 2019 – Crown Bioscience today announced the launch of a new tumor organoid drug development pl... read more
October 01, 2019 Hubrecht Organoid Technology and MIMETAS to d... Leiden, Utrecht September 2019 MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategi... read more
July 17, 2019 Epistem license Hubrecht Organoid Technology ... Epistem license Hubrecht Organoid Technology to expand preclinical toxicology service portfolio Manchester, 16th July, 2... read more